drugset / Trial / NCT01436201

A Study of the Effect of Dulaglutide on How Body Handles Digoxin in Healthy Participants

NCT01436201

Phase 1 Completed 24 enrolled Eli Lilly and Company
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to study how the body processes digoxin and the effect of dulaglutide on how digoxin is processed by the body. Information about any side effects that may occur will also be collected. This study is for research purposes only and is not intended to treat any medical condition. This research study requires that a blood sample be obtained and stored for future research involving genetic analysis.

Timeline

Start
2011-09
Primary completion
2011-11
Completion
2011-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Digoxin Other / unclassified 0.25 mg Oral
Subject Dulaglutide Peptide 1.5 mg Subcutaneous